Cross-sectional Study for Identification and Description of Severe Asthma Patients

Inclusion Criteria:

- At least 12 years of age at study visit.

- Participants eligible for enrolment and entry into the study must meet the following
definition of severe asthma, which is based on the definition of severe asthma
described in the European Respiratory Society/ American Thoracic Society (ERS/ATS)
Guidelines for severe asthma: Asthma which requires treatment with guideline suggested
medications for Global Initiative for Asthma (GINA) steps 4-5 asthma for the previous
year (i.e., at least 12 months).

Patients must be treated with high dose ICS PLUS at least one of the following: LABA,
leukotriene modifier, theophylline, or continuous or near continuous systemic
corticosteroid (i.e., maintenance systemic corticosteroid for ≥50% of the previous year).

SPECIAL CIRCUMSTANCE: If patient is on a fixed dose combination medication, then the
maximum recommended dose of the ICS/LABA combination per local label is acceptable.

- Able to give written informed consent prior to participation in the study, which will
include the ability to comply with the requirements and restrictions listed in the
consent form. Participants must be able to read, comprehend, and write at a level
sufficient to complete study related materials. A parent or legal guardian must
provide informed consent for participants less than 18 years of age at study visit (or
less than minimum age to be considered an adult per local laws).

Exclusion Criteria:

Participants who have participated in an interventional clinical trial for asthma within
the past 12 months prior to Visit 1 (NOTE: subjects participating in an observational study
where an investigational product or procedure is not administered will not be subject to
this exclusion criteria)